A Phase 1/2a Double-Blind, Placebo-controlled, Single- and Multiple Ascending Dose Study to Assess the Safety, Tolerability, PK, PD and Efficacy of IV Administration of ATX-01 In Male and Female Participants Aged 18 to 64 With Classic DM1
Latest Information Update: 12 Mar 2026
At a glance
- Drugs ARTHEx 01 (Primary)
- Indications Myotonic dystrophy
- Focus Adverse reactions; First in man
- Acronyms ArthemiR
- Sponsors ARTHEx Biotech
Most Recent Events
- 21 Jan 2026 Planned End Date changed from 1 Jun 2026 to 1 Jul 2027.
- 21 Jan 2026 Planned primary completion date changed from 1 Jun 2026 to 1 Jul 2027.
- 17 Sep 2025 According to an ARTHEx Biotech media release, initial clinical data expected in 2026.